SBC Medical Group Holdings earnings release, August 13, 2026

SBC Medical Group Holdings Inc (SBC) · Form 8-K, Item 2.02 · Filed · SEC filing

SBC Medical Group Holdings Reports Second Quarter 2026 Financial Results

Restructuring Complete, Growth Reaccelerates: Q2 Revenue Up 13%, Net Income Attributable to SBC Medical Up 335%, Adjusted EBITDA¹

Up 32% Year-over-Year. AI-Enabled Service Enhancements Drive Successful Fee Increases, Positioning the Business for Accelerated Network Expansion —(BUSINESS WIRE)— IRVINE, Calif. -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the second quarter of fiscal year 2026 (the three months ended June 30, 2026) and the first half of fiscal year 2026 (the six months ended June 30, 2026).

■ Second Quarter 2026 Financial Highlights

• Total revenues were

$49 million, an increase of 13% year-over-year.

• Net income attributable to SBC Medical was $11 million, an increase of 335% year-over-year. Net income margin was 22%, an increase of 16 percentage points year-over-year.

• Adjusted EBITDA¹ was

$20 million, an increase of 32% year-over-year. Adjusted EBITDA margin¹ was

41%, an increase of 6 percentage points year-over-year.

• Basic EPS was $0.10 for the three months ended June 30, 2026, an increase of 400% year-over-year.

The Company believes the quarter marked a clear reacceleration in its growth, with net income attributable to SBC Medical growth outpacing revenue growth. Earnings growth was supported by the expansion of the points business following a change in the Company’s operating policy and the expansion of service fees in line with enhanced AI-enabled support capabilities.

The business of the medical corporations the Company supports also continued to expand steadily. As of the end of June 2026, the number of locations² increased by 34 year-over-year to 287, and last-twelve-month number of visits³ reached 6.9 million (up 10% year-over-year). Average spend per visit was $287, up 9% year-over-year.

■ Comment from SBC Medical’s Chairman and CEO Yoshiyuki Aikawa:

“We believe our results this quarter clearly demonstrate that SBC Medical’s growth story has entered a new phase. Having completed the structural reforms we undertook in 2025, we are now running multiple growth engines simultaneously. I am growing increasingly confident that this reacceleration is not a temporary phenomenon but reflects the strengthening of our underlying growth fundamentals.

What gives me the greatest confidence is that the convergence of healthcare and AI is becoming one of SBC Medical’s next sources of competitive advantage. We are leveraging more than 26 years of accumulated management data to support AI development and implementing mechanisms that enhance clinic operations — including AI-powered call centers, AI-driven marketing, and AI-assisted site selection for new clinic openings.

Strengthening our AI-enabled MSO platform simultaneously drives growth across three dimensions: the number of clinic locations, average fee per clinic (AFPC), and service menu breadth. As the platform’s appeal grows, patient visits and treatment volumes at the clinics we support increase, accelerating clinic growth — which in turn leads to expanded service fees commensurate with the value we provide. We believe this virtuous cycle is the driving force behind sustainable growth in consolidated revenue and EPS, as reflected in our most recent reported historical results and in the future.

Specifically, through fee revisions for our call center services provided to five specific affiliated medical corporations, together with separate fee revisions reflecting expanded support for Rize Clinic and Gorilla Clinic, we expect these initiatives, if their impact is realized for a full year, to increase service fees by approximately $15 million annually (converted at ¥158.1/US$). These initiatives are being pursued in a disciplined manner, premised on a win-win relationship between the Company and our affiliated medical corporations.

Looking ahead, we will deepen our multi-brand strategy in aesthetic dermatology domestically, while expanding our non-aesthetic business, which we position as our “second growth engine.” Internationally, we plan to accelerate our global growth through our collaboration with OrangeTwist in the United States and our ASEAN expansion, anchored in Thailand. We are also preparing to enter the Longevity market, which we see as having enormous potential.

With $184 million in cash and cash equivalents on hand, we will continue to pursue disciplined investment toward our next growth phase. By pursuing sustained EPS growth and achieving fair equity valuation for our shares in the capital markets as two wheels of the same cart, we aim to deliver even greater value to all our stakeholders, including our shareholders. We look forward to what lies ahead for SBC Medical.”

■ Summary of Key Financials¹

Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP financial measures. For more information on non-GAAP financial measures, please refer to “Use of Non-GAAP Financial Measures” and “Reconciliation of GAAP to Non-GAAP Measures (unaudited).”²

Represents the total number of locations across the Company’s support and partnership network, including franchised locations of SBC-branded clinics, Rize Clinic, Gorilla Clinic, AHH Clinic, JUN CLINIC, and OrangeTwist.³

Patient visits include patients of SBC-branded clinics, Rize Clinic, Gorilla Clinic, AHH Clinic, and JUN CLINIC. The period covered is from July 1, 2025 to June 30, 2026.⁴

Return on equity (ROE) is calculated as net income attributable to SBC Medical divided by average shareholders’ equity (beginning and end of period).⁵

Basic EPS is calculated as net income attributable to SBC Medical divided by the weighted average number of shares outstanding.

Conference Call... ompany will hold a conference call on Thursday, August 13th, 2026 at 08:30 a.m. Eastern Time (or Thursday, August 13th, 2026 at 09:30 p.m. Japan Time) to discuss the financial results for the second quarter ended June 30, 2026. A question-and-answer session will follow the prepared remarks.

During the live webcast, participants may submit questions in real-time using the Zoom Q&A button.

All attendees, regardless of their current stock ownership status, are welcome to submit questions. Please note that due to time constraints and the nature of the inquiries, we may not be able to address every question during the call.

Please register in advance of the conference using the link provided below: https://zoom.us/webinar/register/WN_sEGnJWOyQDejlpnuGnxQgA

Upon registration, you will be able to access the dedicated conference call viewing site.

Additionally, the earnings release, accompanying slides, and a separate link to the archived webcast of this conference call will be available on the Company’s Investor Relations website at https://ir.sbc-holdings.com/.

About SBC Medical

SBC Medical is a Medical Services Organization providing management support across a wide range of healthcare fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, alopecia treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.

Company Name: SBC Medical Group Holdings Incorporated | Listed Market: NASDAQ Global Market | Ticker: SBC | Address: 200 Spectrum Center Drive, Suite 300, Irvine, CA 92618 USA | IR Website: https://ir.sbc-holdings.com/ | LinkedIn: https://www.linkedin.com/company/sbc-medical-group-holdings-inc

Use of Non-GAAP Financial Measures

The Company uses non-GAAP measures, such as Adjusted EBITDA, Adjusted EBITDA margin, in evaluating its operating results and for financial and operational decision-making purposes. The Company believes that the non-GAAP financial measures help identify underlying trends in its business, provide useful information about the Company’s results of operations, enhance the overall understanding of the Company’s past performance and future prospects, and allow for greater visibility with respect to key metrics used by the Company’s management in its financial and operational decision-making.

The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The presentations of these measures have limitations as analytical tools and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company. For reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures, see the reconciliations included at the end of this press release.

Financial statements

Income Statement

■ Summary of Key Financials

2Q262Q25YoY1H261H25YoY
Total revenues494313.0%92912.0%
Net Income Attributable to SBC Medical112335.0%2224-8.0%
Net Income Margin226+16pt2426(2)pt
Adjusted EBITDA 1201532.0%3840-4.0%
Adjusted EBITDA Margin 14135+6pt4244(2)pt
ROE (Annualized) 4164+12pt1722(5)pt
Basic EPS 50.10.02400.0%0.210.23-9.0%

Income Statement

For the Three Months Ended June 30, — UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

For the Three Months Ended June 30, – 2026For the Three Months Ended June 30, – 2025For the Six Months Ended June 30, – 2026For the Six Months Ended June 30, – 2025
Revenues, net – related parties43,732,19438,944,89881,687,25484,202,043
Revenues, net5,455,8744,413,94910,561,3766,485,505
Total revenues, net49,188,06843,358,84792,248,63090,687,548
Cost of revenues (including cost of revenues from related parties of $138,593 and $4,669,602 for the three months ended June 30, 2026 and 2025, and $262,982 and $8,126,530 for the six months ended June 30, 2026 and 2025, respectively)13,210,75213,348,27025,924,58022,943,887
Gross profit35,977,31630,010,57766,324,05067,743,661
Operating expenses:Selling, general and administrative expenses (including selling, general and administrative expenses from related parties of $341,510 and $415,767 for the three months ended June 30, 2026 and 2025, and $684,903 and $415,767 for the six months ended June 30, 2026 and 2025, respectively)17,016,76615,456,38529,643,48528,987,395
Operating expenses:Total operating expenses17,016,76615,456,38529,643,48528,987,395
Operating expenses:Income from operations18,960,55014,554,19236,680,56538,756,266
Other income (expenses):Interest income8,52022,882129,88978,215
Other income (expenses):Interest expense-128,629-49,651-243,435-55,858
Other income (expenses):Foreign currency exchange gain (loss), net1,032,259-769,7201,893,937-1,828,246
Other income (expenses):Other income137,056145,403628,620296,731
Other income (expenses):Other expenses-455,070-362,745-678,279-1,001,478
Other income (expenses):Gain on redemption of life insurance policies8,746,138
Other income (expenses):Total other income (expenses)594,136-1,013,8311,730,7326,235,502
Other income (expenses):Income before income taxes and equity in losses of equity method investees19,554,68613,540,36138,411,29744,991,768
Other income (expenses):Income tax expense7,823,74311,100,50915,351,33421,059,966
Other income (expenses):Equity in losses of equity method investees, net of tax-568,652-568,652
Other income (expenses):Net income11,162,2912,439,85222,491,31123,931,802
Other income (expenses):Less: net income (loss) attributable to non-controlling interests469,469-18,388490,418-28,884
Other income (expenses):Net income attributable to SBC Medical Group Holdings Incorporated10,692,8222,458,24022,000,89323,960,686
Other comprehensive income (loss):Foreign currency translation adjustment-5,319,4718,623,269-9,569,02018,431,596
Other comprehensive income (loss):Total comprehensive income5,842,82011,063,12112,922,29142,363,398
Other comprehensive income (loss):Less: comprehensive income attributable to non-controlling interests198,369184,411216,664147,579
Other comprehensive income (loss):Comprehensive income attributable to SBC Medical Group Holdings Incorporated5,644,45110,878,71012,705,62742,215,819
Net income per share attributable to SBC Medical Group Holdings IncorporatedBasic and diluted0.10.020.210.23
Weighted average shares outstandingBasic and diluted102,576,943103,507,249102,576,943103,392,580

Income Statement

For the Three Months Ended June 30, — SBC MEDICAL GROUP HOLDINGS INCORPORATED

For the Three Months Ended June 30, – 2026For the Three Months Ended June 30, – 2025For the Six Months Ended June 30, – 2026For the Six Months Ended June 30, – 2025
Total Revenues, net49,188,06843,358,84792,248,63090,687,548
Net income attributable to SBC Medical Group Holdings Incorporated10,692,8222,458,24022,000,89323,960,686
Adjusted to exclude the following:Net income (loss) attributable to non-controlling interests469,469-18,388490,418-28,884
Adjusted to exclude the following:Equity in losses of equity method investees, net of tax568,652568,652
Adjusted to exclude the following:Income tax expense7,823,74311,100,50915,351,33421,059,966
Adjusted to exclude the following:Gain on redemption of life insurance policies-8,746,138
Adjusted to exclude the following:Other expenses455,070362,745678,2791,001,478
Adjusted to exclude the following:Other income-137,056-145,403-628,620-296,731
Adjusted to exclude the following:Foreign currency exchange gain (loss), net-1,032,259769,720-1,893,9371,828,246
Adjusted to exclude the following:Interest expense128,62949,651243,43555,858
Adjusted to exclude the following:Interest income-8,520-22,882-129,889-78,215
Adjusted to exclude the following:Depreciation and amortization expense1,132,524636,1011,802,9581,264,405
Adjusted to exclude the following:Adjusted EBITDA20,093,07415,190,29338,483,52340,020,671
Adjusted to exclude the following:Net income margin22.0%624.0%26
Adjusted to exclude the following:Adjusted EBITDA margin41.0%3542.0%44

Balance Sheet

June 30, 2026 — UNAUDITED CONSOLIDATED BALANCE SHEETS — (Continued)

June 30, 2026December 31, 2025
Stockholders’ equity:Common stock ($0.0001 par value, 400,000,000 shares authorized, 103,881,251 shares issued, and 102,576,943 shares outstanding as of June 30, 2026 and December 31, 2025)10,38810,388
Stockholders’ equity:Additional paid-in capital75,715,94272,867,424
Stockholders’ equity:Treasury stock (at cost, 1,304,308 shares as of June 30, 2026 and December 31, 2025)-7,749,997-7,749,997
Stockholders’ equity:Retained earnings262,449,513240,448,620
Stockholders’ equity:Accumulated other comprehensive loss-66,589,505-57,294,239
Stockholders’ equity:Total SBC Medical Group Holdings Incorporated stockholders’ equity263,836,341248,282,196
Stockholders’ equity:Non-controlling interests16,078,80115,022,510
Stockholders’ equity:Total stockholders’ equity279,915,142263,304,706
Stockholders’ equity:Total liabilities and stockholders’ equity406,659,022380,447,946

Balance Sheet

For the Six Months Ended June 30, — UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Six Months Ended June 30, – 2026For the Six Months Ended June 30, – 2025
CASH FLOWS FROM OPERATING ACTIVITIESNet income22,491,31123,931,802
Adjustments to reconcile net income to net cash provided by (used in) operating activities:Depreciation and amortization expense1,802,9581,264,405
Adjustments to reconcile net income to net cash provided by (used in) operating activities:Non-cash lease expense2,861,0222,185,744
Adjustments to reconcile net income to net cash provided by (used in) operating activities:Provision for (reversal of) credit losses-44,753283,752
Adjustments to reconcile net income to net cash provided by (used in) operating activities:Equity in losses of equity method investees568,652
Adjustments to reconcile net income to net cash provided by (used in) operating activities:Stock-based compensation7,854
Adjustments to reconcile net income to net cash provided by (used in) operating activities:Fair value change of long-term investments-34,905384,523
Adjustments to reconcile net income to net cash provided by (used in) operating activities:Gain on redemption of life insurance policies-8,746,138
Adjustments to reconcile net income to net cash provided by (used in) operating activities:Loss (gain) on disposal of property and equipment9,397-10,804

Cash Flow

For the Six Months Ended June 30, — UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS — (Continued)

For the Six Months Ended June 30, – 2026For the Six Months Ended June 30, – 2025
CASH FLOWS FROM INVESTING ACTIVITIESPurchase of property and equipment-209,391-560,431
CASH FLOWS FROM INVESTING ACTIVITIESPrepayments for property and equipment-804,423-705,351
CASH FLOWS FROM INVESTING ACTIVITIESPayments made on behalf of related parties-1,836,541
CASH FLOWS FROM INVESTING ACTIVITIESPurchase of long-term investments-652,555
CASH FLOWS FROM INVESTING ACTIVITIESPurchase of cryptocurrencies-424,250
CASH FLOWS FROM INVESTING ACTIVITIESLong-term loans to others-13,134
CASH FLOWS FROM INVESTING ACTIVITIESRepayments from related parties70,000
CASH FLOWS FROM INVESTING ACTIVITIESRepayments from others31,11156,307
CASH FLOWS FROM INVESTING ACTIVITIESProceeds from redemption of life insurance policies17,735,717
CASH FLOWS FROM INVESTING ACTIVITIESDeconsolidation of VIE, net of cash disposed of1,019,909
CASH FLOWS FROM INVESTING ACTIVITIESProceeds from disposal of property and equipment1,728,236
CASH FLOWS FROM INVESTING ACTIVITIESNET CASH PROVIDED BY INVESTING ACTIVITIES37,20615,397,998
CASH FLOWS FROM FINANCING ACTIVITIESBorrowings from related parties15,000
CASH FLOWS FROM FINANCING ACTIVITIESProceeds from exercise of stock acquisition rights in subsidiary by non-controlling interests31,866
CASH FLOWS FROM FINANCING ACTIVITIESRepayments of bank and other borrowings-3,740,739-74,256
CASH FLOWS FROM FINANCING ACTIVITIESRepayments of finance lease liabilities-71,942-278,097
CASH FLOWS FROM FINANCING ACTIVITIESRepayments to related parties-22,657-27,943
CASH FLOWS FROM FINANCING ACTIVITIESRepurchase of common stock-2,415,262
CASH FLOWS FROM FINANCING ACTIVITIESDeemed contribution in connection with price modification on disposal of property and equipment9,682,277
CASH FLOWS FROM FINANCING ACTIVITIESNET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES-3,803,4726,901,719
CASH FLOWS FROM FINANCING ACTIVITIESEffect of exchange rate changes-7,437,60711,808,241
CASH FLOWS FROM FINANCING ACTIVITIESNET CHANGE IN CASH AND CASH EQUIVALENTS20,537,37527,696,790
CASH FLOWS FROM FINANCING ACTIVITIESCASH AND CASH EQUIVALENTS AS OF THE BEGINNING OF THE PERIOD163,773,838125,044,092
CASH FLOWS FROM FINANCING ACTIVITIESCASH AND CASH EQUIVALENTS AS OF THE END OF THE PERIOD184,311,213152,740,882
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATIONCash paid for interest expense243,43555,858
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATIONCash paid for income taxes, net8,660,82219,637,454
NON-CASH INVESTING AND FINANCING ACTIVITIESProperty and equipment transferred from long-term prepayments703,529246,188
NON-CASH INVESTING AND FINANCING ACTIVITIESOperating lease right-of-use assets obtained in exchange for operating lease liabilities67,106104,437
NON-CASH INVESTING AND FINANCING ACTIVITIESFinance lease right-of-use assets obtained in exchange for finance lease liabilities612,466
NON-CASH INVESTING AND FINANCING ACTIVITIESRemeasurement of operating lease liabilities and right-of-use assets due to lease modifications4,844,8031,160,680
NON-CASH INVESTING AND FINANCING ACTIVITIESPayables to related parties in connection with loan services provided8,175,342
NON-CASH INVESTING AND FINANCING ACTIVITIESIssuance of common stock as incentive shares86
Full release

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s plans and strategies for service expansion; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” “targets,” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · SBC Medical Group Holdings earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.